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Introduction
Prolonged air leak (PAL) is a dreaded post-operative 
complication of thoracic surgery and a major clinical 
problem in patients with pneumothorax of a medical 
etiology. Although surgical management is considered the 
definitive approach, bronchoscopic techniques have been 
part of the toolkit for decades because many of these patients 
are suboptimal surgical candidates. These endoscopic 
interventions have evolved from crude occlusion devices 
and primitive glues to sophisticated valves and resorbable 
hemostatic sealants. The tools most widely used in current 
practice can all be applied using flexible bronchoscopy. 
Procedural success is typically defined as cessation (or 
at least reduction) of air leak. Whether the chemical or 
device route is chosen, published experience indicates that 
repeat procedures are common owing to incomplete initial 
response. It should be recognized that the body of evidence 
supporting bronchoscopic treatment of PAL is limited to, 
at best, small prospective studies and is subject to numerous 
forms of bias. When the largest series reporting results of 
endoscopic interventions for post-pneumonectomy PAL 
were systematically reviewed in 2007, an overall cure rate of 
only 30% was obtained (1). An additional cautionary note is 
that a systematic review of randomized controlled trials on 
intra-operative sealant application for prevention of air leak 
after lung cancer resectional surgery found that only a small 
minority of these trials showed benefit and therefore firm 
recommendations were withheld (2). This article begins 
with an overview of important definitions and clinical 
considerations pertaining to PAL followed by a discussion 
of the individual bronchoscopic modalities. 
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Definitions
Air leak into the pleural space originating either from an 
airway or lung parenchyma is one of the most common 
complications of thoracic procedures ranging from 
transbronchial biopsy to pneumonectomy, in which case 
the resultant pneumothorax is iatrogenic (3,4). Air leak 
can also give rise to primary spontaneous pneumothorax 
in patients with no grossly evident lung pathology as well 
as secondary spontaneous pneumothorax (SSP) in those 
with underlying pulmonary disease (e.g., emphysema, cystic 
fibrosis, infection, etc.). Another etiology of air leak is chest 
trauma. When the source of air entering the pleural space 
is at the level of a segmental bronchus or more proximal, 
the lesion is termed a bronchopleural fistula (BPF); a more 
distal origin implies the presence of an alveolopleural 
fistula (APF) (5). The preponderance of the literature on 
the subject of air leak is of a surgical nature and therefore 
post-operative BPF dominates the discourse, as it will in the 
present review.
The presence of an air leak is indicated by the detection 
of bubbles in the water seal chamber of the collection 
system connected to the pleural drain. This is a common 
phenomenon during the first 2 days after pulmonary 
resection but persists beyond that only in a small minority 
of patients (6). The severity of air leak is typically classified 
according to the phase of the respiratory cycle during which 
the bubbles appear, and it increases along the following 
continuum: escape of air during forced exhalation maneuver 
only (i.e., cough), during quiet exhalation only (spontaneous 
breathing), during inspiration only (positive pressure 
breathing), and during both inhalation and exhalation (7). 
Drainage systems equipped with digital flow meters 
capable of quantifying the leak are now also available (8). 
Conventionally, an air leak is considered prolonged if it 
persists beyond 5 days after the precipitating event. It is 
the BPF complicated by PAL that poses the most serious 
threat to the patient and the greatest clinical challenge. 
Bronchoscopic interventions to be discussed herein are 
best viewed in the context of this extreme of the disease 
spectrum. 
Epidemiology and clinical features
The most common cause of BPF is resectional thoracic 
surgery, especially pneumonectomy (right more than left) (9) 
and lung volume reduction surgery (LVRS) (10). The 
reported incidence of post-resection BPF varies from 
as low as 2% (11) to as high as 90% (10) depending on 
multiple variables such as type of operation and surgical 
technique. Residual cancer at the resection margin (12) 
and post-operative positive pressure ventilation (13) has 
also been shown to increase the risk. Several patient factors 
predisposing to the development of post-operative BPF 
have been identified; notable among them are low forced 
expiratory volume in 1 second (FEV1) (14), emphysema (15), 
diabetes (16), chronic systemic steroid use (17), and 
neoadjuvant chemotherapy and/or radiation (18). In the 
immediate post-operative period, BPF implies stump 
dehiscence and can present as an acute decompensation 
related to the possibility of empyema, aspiration of pleural 
space contents into one or both lungs, wasted ventilation, 
and tension pneumothorax (19). Delayed (>30 days) post-
surgical BPF is a more indolent illness characterized by 
fever and constitutional symptoms reflective of chronic 
reciprocal soilage of the pleural and alveolar spaces. Besides 
its morbidity and attendant resource utilization, post-
resectional BPF is associated with a significant crude in-
hospital mortality rate, reported to be in excess of 70% 
in one study (12). The basic tenets of the care of the BPF 
patient are to ensure adequate ventilatory support, initiate 
drainage of empyema if present, administer appropriate 
antibiotics, and optimize nutritional status. The definitive 
means of addressing a post-surgical BPF is operative 
closure. Historically, bronchoscopic management of BPF 
has been reserved for patients deemed to be poor candidates 
for re-operation. 
Localization
Pinpointing the site of post-resectional BPF is generally 
straightforward as it is almost always located at the 
bronchial stump. Localization of non-operative BPF and 
APF can be more challenging. Chest computed tomography 
is capable of identifying the location of a peripheral fistula 
by demonstrating a communication between a bronchus 
and the pleural space (20) (Figure 1). The detection of 
bronchoscopically instilled methylene blue in the pleural 
collection chamber would indicate the presence of a 
fistula but would not establish its location. Retrograde 
administration (i.e., from the pleural side), on the other 
hand, can identify the culprit airway based on where the 
dye is encountered at subsequent bronchoscopy (21). The 
use of ventilation scintigraphy has also been described, 
which is predicated on abnormal focal accumulation of 
the inhaled tracer at the site of communication with the 
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pleural space (Figure 2). Both radioisotope-labeled gas (e.g., 
133Xe and 81mKr) and aerosol have been employed for this 
purpose (22). Inhalation of the latter, in the form of 99mTc-
tagged diethylenetriamine pentaacetate (DTPA), was 
performed to detect air leaks of various etiologies in a study 
of 28 patients, which it did with an overall sensitivity of 78% 
and a specificity of 100% (23). Fusion of scintigraphy with 
concomitant single photon emission computed tomography 
(SPECT) could enable more precise localization.
For the purpose of bronchoscopic intervention, real-
time confirmation of the airway feeding the air leak is of 
fundamental importance. Currently, the balloon occlusion 
method described by Ratliff and colleagues in 1977 is the 
most widely used approach (24). This technique involves 
passing a Fogarty® balloon catheter (Edward Lifesciences 
Corp., Irvine, CA, USA) through the instrument channel 
of a flexible bronchoscope, which is then sequentially 
inflated in the lobar bronchi. The cessation or significant 
diminution of air leak following balloon occlusion of a 
given lobar bronchus, which could take up to 2 minutes to 
manifest, identifies it as leading to the fistula. The balloon 
is then similarly inflated in the segmental bronchi and, if 
feasible, the sub-segmental bronchi within the target lobe to 
localize the culprit airway at those generations. Frequently, 
more than one candidate bronchus will be identified. In 
the case of endobronchial valve placement (see below), this 
balloon occlusion test can be performed with an included 
kit that allows for simultaneous sizing of the airway for 
valve selection. Another option is the commercially 
available Chartis® system (Pulmonx, Redwood City, CA, 
USA) designed to assess for the presence of collateral 
ventilation (25). This system provides a balloon catheter that 
is equipped with a flow and pressure sensor. A persistently 
negative pressure after inflation and elimination of air flow in 
an airway indicates communication with a BPF. 
Valves
Endobronchial valves (EBV) are currently the most actively 
explored bronchoscopic modality for the management 
of PAL. They were originally developed and studied as a 
minimally invasive alternative to LVRS. EBVs are designed 
to function as removable one-way barriers that permit air 
and secretions to escape during exhalation but prevent air 
from passing through during inhalation. When applied to 
PAL, the hypothesis is that abolition by the EBV of airflow 
through the airway leading to the fistula will allow the 
defect to seal. Placement is envisioned to be temporary with 
removal after a period of tissue healing. Fann and colleagues 
inserted EBVs into the corresponding segmental bronchus 
of each of six sheep following creation of an air leak due 
to APF for which they first placed a pleural drain (26). 
They were able to achieve rapid resolution of the air leak 
in all animals. The first reported use of EBVs in humans 
to control air leak was published by Snell and colleagues in 
2005 after successful treatment of a patient with intractable 
Figure 1 CT chest showing a communication between a peripheral 
branch of the right middle lobe medial segment bronchus and the 
pleural space (arrow) in a patient with a BPF due to erosive lung 
cancer.
Figure 2 99mTc-DTPA ventilation scintigraphy image showing 
focal radiotracer accumulation in the lower left hemithorax (arrow) 
corresponding to the site of PAL in a patient with left secondary 
spontaneous pneumothorax in the setting of idiopathic pulmonary 
fibrosis.
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pleuro-cutaneous fistula (27). 
Two types of EBVs are currently produced in the United 
States (US): the Emphasys Zephyr® Endobronchial Valve 
System (Pulmonx, Redwood City, CA, USA) and the 
Spiration® Valve System (Olympus Respiratory, Redmond, 
WA, USA). Both are constructed on a Nitinol (nickel-
titanium) frame. The body of the Spiration® EBV is 
umbrella-shaped and made of polyurethane (Figure 3), 
whereas the Zephyr® EBV has a “duck bill” configuration 
and is made of silicone (Figure 4). The Spiration® EBV 
system comes in three different sizes corresponding to 
airway diameters of 5, 6, and 7 mm. The Zephyr® EBV 
system is manufactured in size 4.0 and 5.5 for use in 
airways measuring 4–7 mm and 5.5–8.5 mm, respectively. 
After the target airway is sized by means of the included 
balloon kit, the corresponding EBV is deployed via a 
flexible bronchoscope using the provided delivery catheter 
(Figure 5). When appropriate, valve removal is accomplished 
by grasping it with forceps passed through the instrument 
channel and then pulling out the bronchoscope and forceps 
together with the valve as one unit. As of this writing, only 
the Spiration® product is approved by the US Food and 
Drug Administration (FDA) and available exclusively under 
the Humanitarian Device Exemption Program for post-
operative PAL complicating lung resectional surgery.
In contrast to the other bronchoscopic interventions 
covered in this review, the literature regarding EBV 
placement for PAL includes not only a number of robust 
retrospective series but also prospective observational data 
(Table 1). The earliest series dates to 2009 and reports 
the results of 40 cases of predominantly non-surgical 
PAL managed with Zephyr® EBV insertion (28). The air 
leak was abolished or reduced in 37/40 patients (92.5%), 
allowing pleural drain discontinuation after a median of 
7.5 days. A maximum of 9 valves was placed in any given 
patient. In 8 of the 40 patients (20%), the valves were 
subsequently removed without recurrence. Six patients 
(15%) developed complications, among them valve 
expectoration and malpositioning as well as pneumonia. 
Subsequent smaller case series (29,33) reported similarly 
high control rates with Spiration® EBV in a population 
Figure 3 Diagram of the Spiration® endobronchial valve. Image 
courtesy of Olympus Respiratory.
Figure 4 Depiction of the Zephyr® endobronchial valve. Image 
courtesy of Pulmonx, Inc.
Figure 5 Appearance of the Spiration® endobronchial valve in the 
proximal right middle lobe bronchus as viewed from the bronchus 
intermedius. Image courtesy of Dr. Kassem Harris.
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of mixed surgical and medical PALs, some of which were 
refractory to prior operative interventions. A median of 
approximately three valves per patient were implanted, 
allowing pleural drain removal after about 2 weeks in cured 
cases. No procedural adverse events were reported, and all 
attempted valve extractions were successful. Dooms and 
colleagues prospectively studied 10 patients with post-
resectional PAL, 9 of whom underwent treatment with a 
median of 4 Spiration® EBV (31). Six of the 9 experienced 
durable total or near total cessation of air leak while 
the other 3 had recurrence, albeit at a lower flow rate, 
attributable to valve displacement. Median time to chest 
drain removal was 4 days, including the 3 non-responders 
who were discharged with Heimlich valves and ultimately 
had their drains discontinued at 14 days post-procedure. 
All patients underwent uneventful valve removal and no 
complications occurred that were attributable to the valves. 
In an analogous prospective study, Firlinger and colleagues 
used both EBV systems and were able to successfully 
remove the pleural drains of 10 out of 13 patients (77%) 
with PAL of mostly malignant and infectious etiology (30). 
Most recently, Gilbert and colleagues compiled the 
experience of multiple EBV centers consisting of 75 
patients (out of a total of 112 evaluated for the procedure) 
who received a median of 2.6 valves (32). The rate of air 
leak resolution varied depending on cause of PAL: 100% 
in those with iatrogenic injury versus 58% in the presence 
of underlying lung disease (i.e., SSP). Overall median time 
to cessation of air leak was 4 days, but that number was 
over 2 weeks in successful cases of SSP. Two patients (3%) 
experienced complications deemed related to the valves, 
namely empyema and contralateral pneumothorax. 
Spigots
Bronchial occlusion with silicone for the treatment of BPF 
was first reported over two decades ago (34). Subsequently, 
Watanabe and colleagues developed endobronchial 
Watanabe spigots (EWS®, Novatech, Grasse, France) 
made of silicone that they used to treat 60 patients with 
air leak of various etiologies, in 58 of whom (97%) they 
were able to achieve satisfactory positioning of the device. 
Elimination or reduction of air leak was achieved in nearly 
80% of cases (35). These spigots are coated with barium 
sulfate for radiographic visibility; they have tapered ends 
and come in three sizes (Figure 6). They are grasped with 
forceps introduced through the working channel of the 
bronchoscope and then advanced within the bronchus 
until firmly wedged. The process is repeated if additional 
bronchi need to be occluded. The spigots are later removed 
when clinically feasible. Since the original publication 
by Watanabe, several case series have documented the 
successful use of EWS® in BPF management. The largest, 
by Kaneda and colleagues, reported 21 patients who had 
undergone endobronchial occlusion with a spigot (36). 
Complete resolution of air leak after the initial procedure 
was observed in 6/21 (29%) of patients while 12/21 (57%) 
had reduction in air leak. The latter group required 
Table 1 Summary of the major studies of EBV insertion for PAL
Lead author, 
year
Study design
Number 
of patients 
receiving EBVa
Valve type
Valves/patient 
(mean ± SD or 
median)
Procedural 
success 
rate (%)b
Time to pleural drain 
removalc (mean ± SD or 
median days)
Valve retrieval 
rate (% of 
subjects)
Procedural 
complication 
rate (%)
Travaline 
2009 (28)
Retrospective 40 Zephyr® 2.9±1.9 93 7.5 20 15
Gillespie 
2011 (29)
Retrospective 7 Spiration® 3.5 75 16 71 0
Firlinger  
2013 (30)
Prospective 13/19 Both 1.4±0.7 77 7.6±5 83 0
Dooms  
2014 (31)
Prospective 9/10 Spiration® 4 67 4 100 0
Gilbert  
2016 (32)
Retrospective 75/112 Spiration® 2 56d 4 NR 3
NR, not reported. a, total number of patients evaluated for EBV placement provided after slash where applicable; b, procedural success is 
generally defined as rapid resolution and/or diminution of air leak following the intervention; c, time following EBV implantation; d, data not 
available for all patients.
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additional spigots and/or pleurodesis to achieve complete 
cessation of air leak. Recently, based on work with a canine 
lung model, a new technique has been proposed for the 
placement of EWS® wherein a rotatable biopsy forceps 
(FB-19CR-1, Olympus USA, Central Valley, PA, USA) is 
used to grasp the spigot, which makes it more maneuverable 
and easier to position (37). In Japan, the spigots are 
an established and officially recognized device for the 
management of intractable pneumothorax. They are not 
listed as FDA-approved in the United States. 
Chemical and thermal occlusion
Tissue adhesives
Cyanoacrylate compounds (e.g., n-butyl-2-cyanoacrylate 
marketed as Histoacryl®, Tissue Seal, Ann Arbor, MI, USA) 
are best known for their use in minor laceration repair and 
surgical skin closure. In the 1980s, investigators instilled 
this substance via a flexible bronchoscope into a canine 
model of post-pneumonectomy BPF at the stump (38). 
When the four study dogs were sacrificed and their tracheas 
excised, the stumps were found to be sealed and covered by 
a layer of scar tissue. An early series from Norway describes 
successful closure of BPF with this compound following 
pneumonectomy for lung cancer in two patients (39). More 
recently, a group from Taiwan reported its use for a post-
lung transplant BPF (40). In all three cases administration 
was through a flexible bronchoscope. Scappaticci et al. 
published their experience after accumulating 20 cases of 
BPF treated with instillation of cyanoacrylate (41). Almost 
all were complications of lung resection for carcinoma 
(18/20), and the majority (13/20) were small (<5 mm). 
Overall, successful closure was achieved in 14/20 patients 
(70%), predominantly when performed for small BPF 
(12/13). Chawla et al. applied this compound through 
a flexible bronchoscope using a transbronchial needle 
aspiration catheter for its delivery (42). They treated 9 
patients, 4 of whom had non-surgical BPF. In those four 
cases, balloon occlusion was employed to localize the origin 
of the BPF. Durable closure occurred in 8 of the 9 patients 
with the only failure being a post-pneumonectomy BPF 
>8 mm in size. The pleural drain was removed a maximum 
of 4 days following successful procedures except for a case 
of tuberculous hydropneumothorax in which the drain 
remained in place for 14 days. Those with experience 
in endoscopic application of cyanoacrylates recommend 
withdrawing the delivery catheter immediately upon 
instillation to avoid gluing it to the airway tissue (43). 
They likewise caution about keeping the bronchoscope 
sufficiently far (i.e., at least 4 cm) from the catheter tip 
during administration to avoid inadvertent gluing of the 
instrument channel, which would require urgent rinsing 
of the channel with a solvent such as acetone to restore its 
patency (42). 
Another substance in this category that has been 
described for BPF management is the adhesive formed 
by the combination of bovine serum albumin and 
glutaraldehyde (BioGlue®, CryoLife, Kennesaw, GA, USA). 
Two case series (44,45) include a total of four patients who 
underwent instillation through either a flexible or rigid 
bronchoscope, all achieving successful closure lasting as 
long as 5 months post-procedure. 
Hemostatic agents as sealants
The most documented agent for the bronchoscopic 
treatment of BPF is fibrin glue (Tisseel®, Baxter, Deerfield, 
IL, USA), which is indicated for surgical hemostasis and 
bonding. Its effect is based on biological thrombogenesis 
that occurs when the two components—fibrinogen 
and thrombin—mix at the time of delivery. The fibrin 
plug thus created is ultimately degraded by endogenous 
plasmin, a process that is delayed for as long as 14 days by 
the incorporation of a plasmin inhibitor called aprotinin 
into the product (46). It is hoped that in the interim 
tissue approximation will have taken place by secondary 
intention. In a canine experiment conducted in the 1980s, 
direct application of fibrin glue to an artificially created 
APF significantly decreased the magnitude of air leak 
compared to no intervention (47). Multiple case reports 
(46,48) and series (49-51) describe the application of fibrin 
glue in various amounts (typically 2–5 mL) through both 
Figure 6 Three sizes of endobronchial Watanabe spigots (EWS®). 
Image courtesy of Novatech.
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rigid and flexible bronchoscopes for the treatment of post-
operative BPF. Of special interest is a review of 45 cases of 
post-surgical BPF by Hollaus and colleagues, 29 of which 
were managed with the introduction of fibrin glue via rigid 
bronchoscopy (52). Their sample represents one of the 
largest publications to date on the role of endoscopic BPF 
closure. This approach was restricted to BPF smaller than 
8 mm with no associated empyema, and the fibrin plug was 
reinforced with spongy calf bone if the defect was greater 
than 3 mm in size. Towards the end of the study period, 
the procedure changed from endoluminal instillation 
to submucosal injection of the glue. Of the 29 patients 
treated endoscopically, 9 (31%) were cured and survived 
to discharge free of pleural drains. Seven had successful 
BPF closure (i.e., cessation of the air leak) but still required 
permanent pleural drainage for chronic empyema. Another 
7 experienced failure of the closure attempt. The remaining 
6 patients died in hospital. The rate of initial successful 
endoscopic BPF closure in this sample was therefore at least 
16/29 or 55% depending on the response of the air leaks of 
those who did not survive to discharge (not reported). The 
authors note that eventual BPF recurrence was observed in 
2 of the 16 cases discharged without an air leak (12%).
Coseal® (Baxter, Deerfield, IL, USA) is a polyethylene 
glycol-based hydrogel that closes tissue defects by 
crosslinking with native proteins. It is designed for leak 
repairs during reconstructive vascular surgery and is fully 
resorbed (Figure 7). Mehta and colleagues administered 
this product to 22 patients with PALs, most of them 
non-surgical, through the working channel of a flexible 
bronchoscope using a flexible catheter (53). Cessation of 
air leak was achieved in 19 patients (86%) an average of 
2 days after completing treatment, and the average time 
to pleural drain removal was about 4 days. Three patients 
expectorated the plug without complications, whereas one 
required an emergent bronchoscopy to suction the plug 
from the trachea after developing hypoxemia.
A number of physical hemostatic materials have also been 
deployed through the flexible bronchoscope in individual 
cases to successfully obliterate BPF. One example is the 
insertion of strips cut from an absorbable sponge made from 
purified porcine skin gelatin (Gelfoam®, Pfizer, New York, 
NY, USA). Placement into two left upper lobe segmental 
bronchi was accomplished by feeding the moistened strips 
into the instrument channel with the aid of forceps and 
then flushing them out with saline once the bronchoscope 
was positioned in the desired location (54). In another 
report, organized regenerated cellulose (Surgicel®, Ethicon, 
Somerville, NJ, USA) was inserted in a similar fashion into 
the left mainstem bronchus of a mechanically ventilated 
patient whose BPF at that location was caused by an eroding 
mass (55). To prevent dislodgment of the Surgicel® patch by 
positive pressure ventilation, a Fogarty catheter was left in 
place with the balloon inflated at the closure site to keep the 
seal intact. Two days following the procedure, the patient 
was breathing spontaneously and had no air leak even with 
the balloon deflated. The catheter and pleural drains were 
removed, and the patient was discharged 6 days after the 
procedure. 
Submucosal injections 
In addition to the submucosal injection of fibrin glue 
as performed by Hollaus et al. (see above), the other 
substances that have been introduced through the flexible 
bronchoscope into the submucosa at the site of a BPF fit one 
of two categories: tissue expanders and sclerosing agents. 
Experience with the former is limited to a description of 
two cases in which a suspension of carbon-coated zirconium 
beads in a water-based gel matrix (Durasphere®, Carbon 
Medical Technologies, St. Paul, MN, USA) was injected 
submucosally using a transbronchial aspiration needle (56). 
In one of the two cases, subsequent cyanoacrylate instillation 
was required to abolish a residual air leak. Over time, 
Durasphere® is expected to promote collagen formation 
that would add to its tissue bulking effect. This substance 
is biocompatible but not biodegradable. The injection of 
sclerosing agents such as tetracycline (57), silver nitrate 
Figure 7 Appearance of Coseal® upon instillation into a lobar 
bronchus as it begins to congeal into a plug. Image courtesy of Dr. 
Kassem Harris.
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with (58) or without (59-61) an albumin suspension, pure 
ethanol (62), and ethanolamine (63) appears to initially 
produce BPF closure by causing local tissue edema, 
which is followed by an inflammatory reaction and then 
by granulation tissue that serves as the ultimate seal. Of 
these chemicals, silver nitrate delivered through a flexible 
bronchoscope is the best-described technique and has been 
>80% effective in recent series (61). 
Varoli and colleagues have published their results of 
managing 35 post-resectional BPF with injections of 
polidocanol (Aethoxysklerol®, Kreussler, Wiesbaden, 
Germany), a pharmaceutical designed for sclerotherapy to treat 
spider and varicose veins (64). Successful closure was achieved 
in 23/35 cases (66%), including post-pneumonectomy BPF as 
large as 10 mm. Bronchoscopically injected ethanolamine, a 
related compound, achieved cessation of air leak in 12/15 (80%) 
predominantly medical patients. 
Thermal therapy
Perhaps counterintuitively, the use of ablative energy 
delivered through the flexible bronchoscope for the 
management of BPF has also been described. The premise 
is to induce tissue inflammation that will heal by forming 
scar tissue that pulls the defect closed. While the use 
of argon plasma coagulation is limited to a single case 
report (65), Kiriyama and colleagues have published their 
experience with Nd:YAG laser (power 5–20 W in 0.5-second 
pulses) in 8 patients with post-surgical BPF, reporting 
successful and durable closure in 4 of them (66). 
Miscellaneous
Metallic non-valvular devices
In this category, the most commonly employed item is 
vascular embolization coils, described in case reports and 
small series. Their insertion has been accompanied by the 
concomitant instillation of either cyanoacrylate (67,68) or 
fibrin glue (69,70). One of the most curious approaches to 
endoscopic BPF management described in the literature 
is the deployment of a lead split shot, otherwise known 
as a fishing weight, using a flexible bronchoscope (24). 
The scenario in which this technique was pioneered was 
that of a patient with acute respiratory distress syndrome 
complicated by barotrauma from positive pressure 
ventilation. The plug was threaded onto a guidewire 
positioned in the subsegmental bronchus identified as the 
culprit airway beforehand. It was then pushed forward by 
the tip of the bronchoscope following it along the guidewire 
until it was wedged in place. After this 1977 report, there 
have been no additional published articles documenting the 
placement of lead shots for BPF.
Septal defect closure devices
Amplatzer™ occluders (AO) are well-known in the 
field of cardiology for their use in septal defect closure, 
an application from which they have been adapted for 
management of BPF. They are made of Nitinol mesh with a 
polyester fabric, a combination that provides initial coverage 
and then promotes tissue growth over the device. There are 
two types of such devices that have been used for BPF: the 
AMPLATZER® Septal Occluder and the AMPLATZER® 
Duct Occluder II (St. Jude Medical, St. Paul, MN, USA). 
Both have a slim central waist with a disc on each end 
(Figure 8). The appropriate size for a given BPF depends 
on the dimensions of the stump and length of the fistula 
to be treated. For placement, a guidewire is passed via the 
instrument channel of a flexible bronchoscope and through 
the BPF followed by a sheath. Next, the AO and its distal 
disc are advanced past the fistula and positioned by pulling 
back so that the disc sits flush against the opening. The 
second disc is then delivered to the proximal side of the 
defect. In the largest series, Fruchter and colleagues were 
able to successfully close 9 of 11 (82%) mostly post-surgical 
BPF in mainstem and lobar bronchi with AOs without 
complications (71). The feasibility of this approach has since 
been corroborated by others (72). AMPLATZER® vascular 
plugs (St. Jude Medical, St. Paul, MN, USA), an analogous 
Figure 8 An example of an Amplatzer occluder: AMPLATZER® 
Duct Occluder II. Image courtesy of St. Jude Medical.
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device functionally related to embolization coils, have also 
been applied to BPF treatment by the same group (73). 
These are likewise Nitinol-based, and the deployment 
principle is similar to that of AOs. 
Stents
Stents are the mainstay of bronchoscopic relief of central 
airway obstruction. They have also been used for the 
management of BPF as described in several case reports and 
series. Metallic stents are known to incite an inflammatory 
response that generates granulation tissue. When airway 
patency is the goal, this would be considered an untoward 
effect of stent placement, but when defect closure is desired, 
such overgrowth can be advantageous. In some instances, 
the shape of a stent has been modified to make it better 
suited for coverage of a particular fistula. The largest 
series by Cao and colleagues describes the use of a fully 
covered metallic stent (SigmaMed Industrial Co., Ltd., 
Huaian, China; CZES type) in 9 patients with fistulae, 
7 of which were bronchopleural (74). Resolution of air 
leak was achieved in all 7, and only one patient required 
a repeat procedure for a complication, namely stent 
expectoration. In another review of 7 patients with large 
post-pneumonectomy BPF, Dutau and colleagues deployed 
custom-made fully covered, self-expandable metallic stents 
(SILMET® conical stent, Novatech, La Ciotat, France) via 
rigid bronchoscopy to treat the fistulae with an immediate 
success rate of 100% (75). Pre-procedure measurements of 
the area to be covered by the stent were taken so that the 
midpoint of the customized stent would coincide with the 
defect. The authors intentionally oversized the stents by 
2mm in diameter to allow maximal apposition. Chae and 
colleagues used a custom-designed metallic, fully covered 
stent with its distal third constricted—giving it a “wine 
glass” appearance—in order to allow the thin stem to fit in 
the BPF tract (76). The distal end of stent (the base of the 
“wine glass”) was positioned on the outside of the stump 
in the post-pneumonectomy space while the proximal end 
(the bowl of the “wine glass”) occupied the intact portion 
of the mainstem bronchus. Bronchoscopic inspection 
2 months after the procedure revealed complete closure of 
the BPF. An important drawback of customized stenting is 
the time required to obtain these devices, as this prolongs 
hospitalization and delays therapeutic intervention.
Silicone stents have also been placed using rigid 
bronchoscopy for the management of large post-
pneumonectomy BPF. For instance, a customized Y-shaped 
silicone stent successfully occluded a left mainstem bronchus 
stump dehiscence after trimming the corresponding bronchial 
limb, pushing a cuff link-shaped prosthesis (DJ-FistulaTM, 
Bryan Corp., Woburn, MA) into the stent’s distal lumen, and 
suturing it with silk (77). Additionally, the stent was reinforced 
with Surgicel® and fibrin glue to prevent any residual leaks. 
Ferraroli and colleagues were also able to place a modified 
Dumon® Y stent (Tracheobronxane Y; Novatech SA, La 
Ciotat Cede, France) in a patient with a 2 mm right mainstem 
bronchus stump fistula. The stent’s right limb was occluded with 
silicone material taken from the same stent (78).
Blood patch
The instillation of autologous blood (blood patch) through 
a pleural drain for the successful management of PAL has 
been reported in case series (79). This approach relies 
both on the immediate sealing effect of clotted blood 
and on the resultant pleural inflammation and symphysis. 
Endoscopic, catheter-guided delivery of autologous blood 
has also been described. Wiaterek and colleagues reported 
a patient with necrotizing pneumonia complicated by 
pneumothorax and PAL. Using flexible bronchoscopy and 
forceps, several layers of a hemostatic agent were applied 
first (Surgicel®, Ethicon, Piscataway, NJ, USA) followed 
by instillation of 3 mL of autologous blood via a modified 
Fogarty® balloon catheter, resulting in immediate cessation 
of air leak (80). The pleural drain was removed after two 
days. In a case series of nine emphysema patients with 
PAL despite spigot placement (EWS®, Novatech, Grasse, 
France), bronchoscopic instillation of autologous blood 
plus thrombin was performed through a 2.45 mm catheter 
(PW-1L-1 and PW-5L-1, Olympus, Tokyo, Japan) passed 
into the gap between the spigot and the bronchial wall and 
directed peripherally under fluoroscopic guidance (81). The 
process was repeated if air leak persisted; the total amount 
of blood administered in each case did not exceed 25 mL. 
Air leak cessation was eventually achieved in 7/9 patients 
(77%) with diminution in the remaining 2. However, in 3 of 
the 7 successful cases, air leak was fully abolished only after 
subsequent pleurodesis. 
Conclusions
Bronchoscopic interventions for PAL represent an evolving 
field within interventional pulmonology (Table 2). While 
they have yet to supplant operative management as the gold 
standard, particularly for larger defects, their place in the 
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armamentarium may change over time as currently available 
techniques are refined and new ones are introduced. The 
endoscopic approach holds great appeal because of its 
relatively low invasiveness, which is of great value for the 
PAL patient who is at high surgical risk. This procedural 
category is sorely lacking comparative studies, but there 
is reason to believe that registry data and multicenter 
collaborations will help narrow the evidence gap in the not-
too-distant future. 
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